CRU Global has entered into an official collaboration aimed at advancing clinical trials and bioanalytical testing

In March, the company signed an official collaboration agreement with QUINTA-ANALYTICA, a member of the Conscio group, solidifying their partnership in the fields of clinical trials and bioanalytical testing.

The agreement was signed by Roman Grunt, CEO of Quinta-Analytica, and Peter Kovacs dr, CEO of CRU Global Network. We believe that the partnership represents a significant step forward in promoting research and innovation in pharmaceutical development.

By combining the expertise, knowledge, and capabilities of both companies, this agreement represents a highly robust collaboration poised to make a substantial contribution to the advancement of clinical trials in the biotechnology and pharmaceutical industries.